The COVID-19 pandemic: progress in nephrology

María José Soler; Conxita Jacobs-Cachá

doi:10.1038/s41581-021-00521-4

The COVID-19 pandemic: progress in nephrology

Nat Rev Nephrol. 2022 Feb;18(2):80-81. doi: 10.1038/s41581-021-00521-4.

Authors

María José Soler¹, Conxita Jacobs-Cachá²

Affiliations

¹ Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain. mjsoler01@gmail.com.
² Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain.

Abstract

Patients with kidney disease are particularly vulnerable to COVID-19. In 2021, key studies demonstrated the safety of renin–angiotensin blockade in patients with kidney failure and COVID-19, and provided new data on the therapeutic potential of soluble angiotensin-converting enzyme, COVID-19 vaccine responses and the long-term effects of COVID-19 on kidney function.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Humans
Nephrology*
Pandemics*